Tuberculosis (TB)

People who use drugs

People who use drugs are at increased risk of TB, with rates documented in the pre-AIDS era of over 10 times higher than among the general population. HIV further increases the risk of TB, and TB is a leading AIDS-defining illness and cause of mortality among people living with HIV who inject drugs. The convergence of viral hepatitis, HIV, TB and injecting drug use has become a major health concern and can have important implications for case management.

WHO strongly supports harm reduction as an evidence-based approach to caring for people who inject drugs and has defined a comprehensive package of harm reduction which includes the prevention, diagnosis and treatment of tuberculosis as a core component. For the latest guidance on integrated care for people who inject drugs, please visit the link below.

Events

2014

Increasing access to TB services as part of integrated care for PWID

21 July 2014 | AIDS2014, Melbourne, Victoria, Australia

The World Health Organization organized an AIDS 2014 conference workshop aimed at increasing access to TB services as part of integrated care for PWID on 21st July 2014 in Melbourne, Australia. The workshop was chaired by Haileyesus Getahun and attended by some 100 participants. Workshop participants were introduced to the upcoming new policy guidance on integrated TB, HIV, viral hepatitis and harm reduction services and examples of integrating TB services into harm reduction services for PWID in Indonesia and Ukraine were shared. Further details can be found at the link below:


2013

Focus on tuberculosis at the 23rd International Harm Reduction Conference

9-12 June 2013 | Vilnius, Lithuania

The 23rd International Harm Reduction Conference in Lithuania brought together some 1000 participants, including front-line harm reduction workers, researchers, policy makers, politicians, people from international organizations, people who use drugs and people working in criminal justice, offering an ideal opportunity to raise the profile of tuberculosis and TB/HIV. TB received more focus at the conference than in previous years with a number of side events organized as well as a major session entitled "An added value: harm reduction and the tuberculosis epidemic", chaired by Smiljka de Lussigny of WHO Euro office and Anya Sarang President of the Andrey Rylkov Foundation for Health and Social Justice in Moscow. The session highlighted the urgent need to include TB prevention and care, including the collaborative TB/HIV activities within the Integrated Package of harm reduction, discussed the barriers to access, and models of integration were shared with participants. A link to presentations from the session can be found at the link below.


Case Study of Integrated Care for People who Inject Drugs

This report from Ukraine offers practical insight and real world models for programme managers, civil society and other stakeholders considering the implementation of collaborative TB/HIV services for people who inject drugs in similar settings. Click below to access the report.